Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System
Authors:
- 3 January 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (1) , e2251833
Abstract
Immunocompromised individuals (ie, persons with immunocompromising conditions or who are taking immunosuppressive medications) are at increased risk for severe COVID-19.1 Additionally, immunocompromised individuals often mount weaker immune responses to vaccines and experience higher rates of vaccine failure compared with immunocompetent individuals.2-5 The US Food and Drug Administration (FDA) and the US Centers for Disease Control and Prevention (CDC) have progressively amended COVID-19 vaccine authorizations and recommendations to include additional doses of COVID-19 vaccine for immunocompromised individuals.6,7 Following the 2-dose mRNA recommendation in December 2020, the CDC Advisory Committee on Immunization Practices recommended in August 2021 that individuals with immunocompromising conditions who had received any mRNA vaccine should receive a third dose as part of their primary series.6 In September 2021, an mRNA monovalent booster dose administered 6 months or more after completion of a primary series of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) was recommended for certain high-risk individuals, including immunocompromised individuals. For immunocompromised individuals, this booster dose corresponded to a fourth dose to follow the recommended 3-dose primary series in this population. In October 2021, the booster recommendation was expanded to recipients of any mRNA vaccine and the interval between completion of a primary series and receipt of a first booster dose was shortened to at least 5 months after completion of a primary series. In February 2022, the recommended interval between a 3-dose primary series and receipt of a first booster (ie, fourth) dose was again shortened for immunocompromised individuals, this time to at least 3 months after completion of a primary series. In March 2022, the CDC announced that immunocompromised individuals could receive a second mRNA monovalent booster of COVID-19 vaccine (ie, a fifth dose) at least 4 months after receiving their first booster (ie, their fourth dose). In May 2022, this recommendation was revised to specify that immunocompromised individuals should receive a second booster (ie, fifth dose).Keywords
This publication has 25 references indexed in Scilit:
- COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based SurveyJMIR Public Health and Surveillance, 2022
- Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active TreatmentJAMA Oncology, 2021
- Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic reviewClinical Microbiology and Infection, 2021
- The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Protection of BNT162b2 Vaccine Booster against Covid-19 in IsraelNew England Journal of Medicine, 2021
- COVID-19 vaccination in kidney transplant recipientsNature Reviews Nephrology, 2021
- COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fearClinical and Translational Science, 2021
- Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)Clinical Infectious Diseases, 2020
- Validation of a Method to Identify Immunocompromised Patients with Severe Sepsis in Administrative DatabasesAnnals of the American Thoracic Society, 2016
- Sociodemographic Characteristics of Members of a Large, Integrated Health Care System: Comparison with US Census Bureau DataThe Permanente Journal, 2012